Canadian Manufacturing

Pharmascience celebrates 40 year anniversary

by CM staff   

Manufacturing Operations Research & Development Public Sector generic drugs Pharmascience R&D investments specialty drugs


In recognition of its 1,500 employees, Pharmascience organized an event on June 19 to launch its 40th year celebrations both at its head office and its production facilities in Montreal and Candiac Quebec.

MONTREAL — Pharmascience is celebrating its 40th anniversary and continues to improve access, secure local supply and offer  medicines for all.

In recognition of its 1,500 employees, Pharmascience organized an event on June 19 to launch its 40th year celebrations both at its head office and its production facilities in Montreal and Candiac Quebec. Gracia Kasoki Katahwa, mayor of the Notre-Dame-de-Grâce and Côte-des-Neiges borough, was present at Royalmount, while the city’s mayor, Normand Dyotte, was attending at Candiac.

“Pharmascience is marking its 40th anniversary with the expansion of its Candiac facilities, and to have this great Quebec family business among its corporate citizens is a source of pride for the municipal council,” said Candiac mayor Normand Dyotte. “Pharmascience’s reputation and worldwide success can only benefit the entire community. I offer my most sincere congratulations to Pharmascience on this milestone anniversary and wish all its employees continued success!”

Founded by pharmacists Morris Goodman and the late Ted Wise is the largest Canadian-owned pharmaceutical company, serving both the Canadian and international markets.

Over the past four decades, Pharmascience has developed pharmaceutical products, including generic drugs, specialty drugs through its Pendopharm division, bioanalytical services through its Royalmount Laboratories division and over-the-counter drugs with its Norwell Canada entity.

“More than ever, we are committed to invest in Canada to enhance the health and well-being of patients all around the world, as demonstrated by our plans to expand our Candiac plant, R&D investments and enviable pipeline” said Martin Arès, CEO at Pharmascience.

Advertisement

Stories continue below

Print this page

Related Stories